Guided Therapeutics to Develop Esophageal Cancer Product; Acquires Intellectual Property Rights from Konica Minolta

  Guided Therapeutics to Develop Esophageal Cancer Product; Acquires
  Intellectual Property Rights from Konica Minolta

Business Wire

NORCROSS, Ga. -- February 6, 2013

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced it has
acquired world-wide rights to develop a non-invasive esophageal cancer
detection product from Konica Minolta. The product will be based on Guided
Therapeutics’ patented biophotonic technology platform.

Under terms of the agreement, Guided Therapeutics acquired both the rights it
had licensed to Konica Minolta, and the rights to certain intellectual
property invented by Konica Minolta. Upon FDA approval, Konica Minolta would
receive a royalty for its licensed intellectual property, if used in the final
product. In addition, Guided Therapeutics will now have full worldwide sales
and marketing rights, as opposed to a royalty only, as was anticipated under
the previous arrangement.

“Konica Minolta has been an excellent partner in helping us to jump start the
development of this promising early cancer detection technology, by
contributing significant resources directly to Guided Therapeutics in the form
of non-dilutive funding,” said Mark L. Faupel, Ph.D., CEO and President of
Guided Therapeutics. “The potential market for this product is significant and
we believe that the best way to maximize shareholder value is to complete
product development independently using the two companies’ combined
intellectual property. At the same time, we also reserve the option to partner
with a new, more healthcare-focused company.”

Going forward, Guided Therapeutics will be responsible for the clinical,
regulatory and product development process. Devices and other resources to be
used for clinical trials, which could begin later this year, are already at or
near completion. In order to complete development of the product, the company
has made progress toward securing additional funding, which could come either
from a new potential partner or other sources.

“Having access to the intellectual property necessary for commercializing the
product, especially at this latter stage of its development, optimizes
shareholder value in our platform technology,” said Dr. Faupel. “The recent
good news from FDA that our esophageal cancer detection product is a
non-significant risk and does not require an investigational device exemption
also supports this value proposition.”

According to the World Health Organization esophageal cancer ranks just below
cervical cancer in newly diagnosed cases. New cases of esophageal cancer are
estimated at 410,000 worldwide, with more than 16,000 new cases a year and
more than 14,000 deaths in the U.S. alone. Barrett’s esophagus is believed to
be caused by excessive acid reflux.

About The Technology Platform

The Guided Therapeutics disease detection platform, which consists of a base
unit and single-patient-use calibration disposable, scans tissue with light to
identify cancer and pre-cancer painlessly and non-invasively. The proprietary,
patented biophotonic technology is able to distinguish between normal and
diseased tissue by detecting biochemical and morphological changes at the
cellular level. Unlike traditional tests, the Guided Therapeutics test does
not require laboratory analysis or a tissue sample, is designed to provide
results immediately and eliminate costly, unnecessary testing.

The first product developed from the technology is the LuViva^® Advanced
Cervical Scan. Unlike Pap, HPV tests or biopsies, LuViva does not require
laboratory analysis or a tissue sample, and is designed to provide results
immediately, which eliminates costly, painful and unnecessary testing. LuViva
is designed for use with women who have undergone initial screening and are
called back for follow up with a colposcopy examination, which in many cases,
involves taking a biopsy of the cervix. The device is used in conjunction with
the LuViva^® Cervical Guide single-use patient interface and calibration

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid
and painless testing platform for the early detection of disease based on its
patented biophotonic technology that utilizes light to detect disease at the
cellular level. The Company’s first planned product is the LuViva® ^ Advanced
Cervical Scan, a non-invasive device used to detect cervical disease instantly
and at the point of care. In a multi-center clinical trial, with women at risk
for cervical disease, the technology was able to detect cervical cancer up to
two years earlier than conventional modalities, according to published
reports. Guided Therapeutics is also developing a non-invasive test for the
early detection of esophageal cancer using the technology platform. For more
information, visit:

The Guided Therapeutics LuViva^® Advanced Cervical Scan is an investigational
device and is limited by federal law to investigational use. LuViva, the wave
logo and "Early detection, better outcomes" are registered trademarks owned by
Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject
areas discussed in this news release that are not historical or current facts
deal with potential future circumstances and developments. The discussion of
such matters and subject areas is qualified by the inherent risks and
uncertainties surrounding future expectations generally and also may
materially differ from Guided Therapeutics’ actual future experience involving
any of or more of such matters and subject areas. Such risks and uncertainties
include those related to the early stage of products in development, the
uncertainty of market acceptance of products, the uncertainty of development
or effectiveness of distribution channels, the intense competition in the
medical device industry, the uncertainty of capital to develop products, the
uncertainty of regulatory approval of products, dependence on licensed
intellectual property, as well as those that are more fully described from
time to time under the heading “Risk Factors” in Guided Therapeutics’ reports
filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K
for the fiscal year ended December 31, 2011, and subsequent quarterly reports.


Cameron Associates
Alison Ziegler, 212-554-5469
Guided Therapeutics
Bill Wells, 770-242-8723
Press spacebar to pause and continue. Press esc to stop.